United Kingdom Genetic Testing Market Outlook to 2024

Published : Nov-2017

No. of Pages : 72

order by fax Inquire before Buying request discount

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Genetic Testing Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Genetic Testing Market, United Kingdom 7
3.1 Genetic Testing Market, United Kingdom, Revenue ($m), 2010-2017 7
3.2 Genetic Testing Market, United Kingdom, Revenue ($m), 2017-2024 9
3.3 Genetic Testing Market, United Kingdom, Distribution Share by Revenue ($m), 2017 11
3.4 Genetic Testing Market, United Kingdom, Company Share by Revenue ($m), 2017 12
4 Overview of Key Companies in United Kingdom, Genetic Testing Market 14
4.1 F. Hoffmann-La Roche Ltd 14
4.1.1 Company Overview 14
4.2 PerkinElmer Inc 14
4.2.1 Company Overview 14
4.3 Abbott Laboratories 14
4.3.1 Company Overview 14
4.4 Hologic Inc 15
4.4.1 Company Overview 15
4.5 Qiagen NV 15
4.5.1 Company Overview 15
4.6 Myriad Genetics Inc 15
4.6.1 Company Overview 15
5 Genetic Testing Market Pipeline Products 16
6 Financial Deals Landscape 18
6.1 Asset Transactions 18
6.1.1 Agilent Technologies Acquires Next Generation Sequencing IP Portfolio from Population Genetics Technologies 18
6.2 Equity Offerings 19
6.2.1 Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 19
6.2.2 Proteome Sciences Raises USD1.3 Million in Second and Final Tranche of Private Placement of Shares 20
6.2.3 Proteome Sciences Raises USD2.8 Million in First Tranche of Private Placement of Shares 21
6.3 Partnerships 22
6.3.1 NuGEN Technologies Enters into Agreement with Cambridge Epigenetix 22
6.3.2 AstraZeneca Enters into Partnership with DNAnexus 23
6.3.3 Lucigen Enters into Distribution Agreement with Illumina 24
6.3.4 SenzaGen Enters into Agreement with AstraZeneca 25
6.3.5 Sophia Genetics Enters into Agreement with Horizon Discovery Group 26
6.4 Venture Financing 27
6.4.1 Biofortuna Raises USD2 Million in Venture Financing 27
6.4.2 Congenica Raises USD10 Million in Series B Financing 28
6.4.3 Atlas Genetics Raises USD35 Million in Series D Financing 29
7 Recent Developments 31
7.1 Corporate Communications 31
7.1.1 Oct 03, 2017: Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman 31
7.1.2 Oct 03, 2017: Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman 31
7.1.3 Sep 15, 2017: Oxford BioDynamics appoints Paul Stockdale as Chief Financial Officer and Executive Director on the Board 32
7.1.4 Sep 01, 2017: Pfizer Receives FDA Approval for Mylotarg (Gemtuzumab Ozogamicin) 32
7.1.5 Sep 01, 2017: Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection 33
7.1.6 Aug 01, 2017: Proteome Sciences: Directorate changes 35
7.1.7 Jun 30, 2017: Oxford BioDynamics: Appointment of Paul Stockdale as Chief Financial Officer 35
7.1.8 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer 36
7.1.9 Mar 09, 2017: Oxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development 36
7.1.10 Feb 16, 2017: Almac Diagnostics Appoints Dr Leeona Galligan as Vice President UK Operations 37
7.1.11 Feb 13, 2017: Oxford BioDynamics appoints Dr Claudio Carini as an Advisor 37
7.2 Financial Announcements 38
7.2.1 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 38
7.2.2 Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific 38
7.2.3 Jun 13, 2017: Oxford Biodynamics Interim Results For The Six-Month Period Ended 31 March 2017 39
7.2.4 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM 43
7.2.5 Jan 31, 2017: Oxford BioDynamics Announces Final Results for the Year Ended 30 September 2016 51
7.2.6 Nov 28, 2016: Toshiba Medical Launches New MR System for Efficient and Standardized Cardiac Exams 52
7.2.7 Nov 22, 2016: OGT announces commercial and financial highlights for FY 2016 53
7.3 Government and Public Interest 54
7.3.1 Feb 22, 2017: NICE recommends wider use of tests to detect cancer-causing genetic condition 54
7.3.2 Nov 15, 2016: One thousand cancer patients have gene testing through efficient, affordable new process 55
7.4 Legal And Regulatory 56
7.4.1 Oct 23, 2017: Almac Group Announces Successful MHRA Inspection at Charnwood Facilities 56
7.4.2 Oct 18, 2017: Proteome Sciences: GCLP Accreditation and Trading Update 56
7.4.3 Jul 03, 2017: Premaitha Health Litigation Update 57
7.4.4 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 57
7.4.5 Jun 12, 2017: Proteome Sciences: New Registered Address 57
7.5 Other Significant Developments 57
7.5.1 Jun 07, 2017: Almac Group Reports Pre-tax Profits of £27M 57
7.5.2 May 25, 2017: Saphetor Signs Multiple Service Agreements with University College London to Analyze Exome and Whole-Genome Sequencing Data 58
7.5.3 Jan 23, 2017: Oxford BioDynamics enters into pilot project with EpiFit to analyse the effect of fitness regimes using EpiSwitch 58
7.5.4 Nov 17, 2016: Horizon Discovery Partners with Sophia Genetics on NGS Reference Standards for Oncology Applications 59
7.6 Product News 60
7.6.1 Oct 03, 2017: Oxford BioDynamics announces grant of US patent for its proprietary technology platform, EpiSwitch 60
7.6.2 Aug 21, 2017: Safer Down's test for pregnant women to be introduced in Wales 60
7.6.3 May 31, 2017: Nature (Scientific Reports) publication highlights advantages of EpiSwitch technology platform 61
7.6.4 Apr 25, 2017: OGT's expanded NGS cancer panels enable sequencing of difficult genes 61
7.6.5 Jan 25, 2017: New generation Syngene gel doc systems for gel and blot imaging to be showcased on stand 140 at ArabLab 2017 62
7.6.6 Jan 16, 2017: genedrive Reports Delivery of Genedrive Units and Assays to the US Department of Defense in Programme to Develop a Handheld Biohazard Identifier 62
7.6.7 Dec 12, 2016: Oxford BioDynamics presents applications of its epigenetic biomarker technology EpiSwitch at the annual meeting of the American Society of Hematology in San Diego 63
7.7 Strategy And Business Planning 63
7.7.1 Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 63
7.7.2 Nov 10, 2016: Almac Announce £27 million Global Expansion 64
8 Appendix 66
8.1 Research Methodology 67
8.1.1 Coverage 67
8.1.2 Secondary Research 67
8.1.3 Primary Research 68
8.1.4 Market Modeling and Forecasting 69
8.1.5 Company Share Analysis 70
8.1.6 Distribution Share Analysis 71
8.1.7 Benchmarking 71
8.2 GlobalData Consulting 71
8.3 Contact Us 72
8.4 Disclaimer 72

1.1 List of Tables
Table 1: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2010-2017 8
Table 2: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2017-2024 10
Table 3: Genetic Testing Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2017 11
Table 4: Genetic Testing Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2017 13
Table 5: Genetic Testing Market Pipeline Products 16
Table 6: Agilent Technologies Acquires Next Generation Sequencing IP Portfolio from Population Genetics Technologies 18
Table 7: Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 19
Table 8: Proteome Sciences Raises USD1.3 Million in Second and Final Tranche of Private Placement of Shares 20
Table 9: Proteome Sciences Raises USD2.8 Million in First Tranche of Private Placement of Shares 21
Table 10: NuGEN Technologies Enters into Agreement with Cambridge Epigenetix 22
Table 11: AstraZeneca Enters into Partnership with DNAnexus 23
Table 12: Lucigen Enters into Distribution Agreement with Illumina 24
Table 13: SenzaGen Enters into Agreement with AstraZeneca 25
Table 14: Sophia Genetics Enters into Agreement with Horizon Discovery Group 26
Table 15: Biofortuna Raises USD2 Million in Venture Financing 27
Table 16: Congenica Raises USD10 Million in Series B Financing 28
Table 17: Atlas Genetics Raises USD35 Million in Series D Financing 29
Table 18: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 69

1.2 List of Figures
Figure 1: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2010-2017 7
Figure 2: Genetic Testing Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2017-2024 9
Figure 3: Genetic Testing Market, United Kingdom, Company Share (%) 2017 12

Filed in: In Vitro Diagnostic, Medical Device

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026 “The global in vitro fertilization market size is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1 % during the forecast period” The global in vitro fertilization market is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1% from 2021 to 2026. The key factors fueling the growth of this market include an increase in the median age of first-time mothers, declining fertility rates, rising male infertility, rise in obesity rate and growing consumption of alcohol, and growing awareness about the availability of treatment options. However, the high cost and low success rate of IVF treatment and restrictive regulations and ethical concerns are expected to restrict the growth of the IVF market to a certain e......	$4950
Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact) Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within General Surgery therapeutic area. The model discusses in detail the impact of COVID-19 on Assisted Reproductive Technology Devices market for the year 2020 and beyond. Assisted Reproductive Technology (ART) refers to reproductive health procedures that treat infertile women to achieve pregnancy. For decades now across much of the developed world, several techniques of ART have been in use with varying pregnancy success rates. These techniques primarily include, but are no......	$7500
Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic preg......	$7500
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028 Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......	$10995
Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......	$7500
Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......	$7500
EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......	$7500
Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......	$7500
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model "Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......	$7500
Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......	$7500

United Kingdom Genetic Testing Market Outlook to 2024

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026

Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model